OncoCyte Corporation (OCX)

OncoCyte Statistics

Total Valuation

OncoCyte has a market cap or net worth of $45.62 million. The enterprise value is $46.25 million.

Market Cap	45.62M
Enterprise Value	46.25M

Important Dates

The last earnings date was Tuesday, November 12, 2024, after market close.

Earnings Date	Nov 12, 2024
Ex-Dividend Date	n/a

Share Statistics

OncoCyte has 16.84 million shares outstanding. The number of shares has increased by 52.77% in one year.

Current Share Class	16.84M
Shares Outstanding	16.84M
Shares Change (YoY)	+52.77%
Shares Change (QoQ)	+6.56%
Owned by Insiders (%)	6.81%
Owned by Institutions (%)	7.24%
Float	6.84M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	41.22
Forward PS	21.59
PB Ratio	3.73
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	65.23
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.53, with a Debt / Equity ratio of 0.41.

Current Ratio	0.53
Quick Ratio	0.39
Debt / Equity	0.41
Debt / EBITDA	0.01
Debt / FCF	n/a
Interest Coverage	-341.52

Financial Efficiency

Return on equity (ROE) is -165.32% and return on invested capital (ROIC) is -48.27%.

Return on Equity (ROE)	-165.32%
Return on Assets (ROA)	-18.84%
Return on Capital (ROIC)	-48.27%
Revenue Per Employee	$15,413
Profits Per Employee	-$948,043
Employee Count	46
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -32.08% in the last 52 weeks. The beta is 1.00, so OncoCyte's price volatility has been similar to the market average.

Beta (5Y)	1.00
52-Week Price Change	-32.08%
50-Day Moving Average	2.97
200-Day Moving Average	2.95
Relative Strength Index (RSI)	41.80
Average Volume (20 Days)	64,472

Short Selling Information

The latest short interest is 194,186, so 1.15% of the outstanding shares have been sold short.

Short Interest	194,186
Short Previous Month	189,327
Short % of Shares Out	1.15%
Short % of Float	2.84%
Short Ratio (days to cover)	6.91

Income Statement

In the last 12 months, OncoCyte had revenue of $709,000 and -$43.61 million in losses. Loss per share was -$4.04.

Revenue	709,000
Gross Profit	116,000
Operating Income	-22.88M
Pretax Income	-36.35M
Net Income	-43.61M
EBITDA	-21.56M
EBIT	-22.88M
Loss Per Share	-$4.04

Balance Sheet

The company has $3.36 million in cash and $3.99 million in debt, giving a net cash position of -$628,000 or -$0.04 per share.

Cash & Cash Equivalents	3.36M
Total Debt	3.99M
Net Cash	-628,000
Net Cash Per Share	-$0.04
Equity (Book Value)	9.71M
Book Value Per Share	0.73
Working Capital	-4.30M

Cash Flow

In the last 12 months, operating cash flow was -$19.78 million and capital expenditures -$566,000, giving a free cash flow of -$21.86 million.

Operating Cash Flow	-19.78M
Capital Expenditures	-566,000
Free Cash Flow	-21.86M
FCF Per Share	-$1.30

Margins

Gross Margin	16.36%
Operating Margin	-3,227.36%
Pretax Margin	-6,085.19%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-1,651.42%

Dividends & Yields

OncoCyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-52.77%
Shareholder Yield	-52.77%
Earnings Yield	-95.59%
FCF Yield	-47.91%

Analyst Forecast

The average price target for OncoCyte is $4.42, which is 63.10% higher than the current price. The consensus rating is "Buy".

Price Target	$4.42
Price Target Difference	63.10%
Analyst Consensus	Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Splits

The last stock split was on July 25, 2023. It was a reverse split with a ratio of 0.05:1.

Last Split Date	Jul 25, 2023
Split Type	Reverse
Split Ratio	0.05:1

Scores

OncoCyte has an Altman Z-Score of -7.15 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-7.15
Piotroski F-Score	1